Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Non-Hodgkin Lymphoma - Pipeline Review, H2 2011
Reference Code: GMDHC1309IDB
Publication Date: September 2011
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 16
List of Figures 22
Introduction 23
Global Markets Direct Report Coverage 23
Non-Hodgkin Lymphoma Overview 24
Therapeutics Development 25
An Overview of Pipeline Products for Non-Hodgkin Lymphoma 25
Non-Hodgkin Lymphoma Therapeutics under Development by Companies 27
Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 33
Late Stage Products 49
Comparative Analysis 49
Mid Clinical Stage Products 50
Comparative Analysis 50
Early Clinical Stage Products 51
Comparative Analysis 51
Discovery and Pre-Clinical Stage Products 52
Comparative Analysis 52
Non-Hodgkin Lymphoma Therapeutics - Products under Development by Companies 53
Non-Hodgkin Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 69
Companies Involved in Non-Hodgkin Lymphoma Therapeutics Development 113
Bristol-Myers Squibb Company 113
Genzyme Corporation 113
Johnson & Johnson 114
Boehringer Ingelheim GmbH 114
F. Hoffmann-La Roche Ltd. 115
Kyowa Hakko Kirin Co., Ltd. 115
Abbott Laboratories 116
Amgen Inc. 116
Sanofi-Aventis 117
AstraZeneca PLC 117
Eli Lilly and Company 118
GlaxoSmithKline plc 118
Seattle Genetics, Inc. 119
Antigenics, Inc. 120
MMR Information Systems, Inc. 121
Biotec Pharmacon ASA 121
MedImmune LLC 122
Gilead Sciences, Inc. 122
Merck & Co., Inc. 123
Emergent BioSolutions Inc. 123
Lentigen Corporation 124
Micromet, Inc. 124
Gamida Cell Ltd. 125
Takeda Pharmaceutical Company Limited 125
ZIOPHARM Oncology, Inc. 126
Millennium Pharmaceuticals, Inc. 126
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Novartis AG 127
Astellas Pharma Inc. 128
Biocon Limited 128
BioMarin Pharmaceutical Inc. 129
Cephalon, Inc. 129
Dong-A Pharmaceutical Co., Ltd. 130
Eisai Co., Ltd. 130
Genta Incorporated 131
Glenmark Pharmaceuticals Ltd. 131
Human Genome Sciences, Inc. 132
ImmunoGen, Inc. 132
Pfizer Inc. 133
Sunesis Pharmaceuticals, Inc. 133
SuperGen, Inc. 134
Cell Therapeutics, Inc. 134
Genmab A/S 135
Astex Therapeutics Limited 135
Cyclacel Pharmaceuticals Inc. 136
Alfacell Corporation 136
Celgene Corporation 137
Bayer AG 137
Merck KGaA 138
Hana Biosciences, Inc. 138
IMMUNOMEDICS, INC 139
InNexus Biotechnology Inc. 139
AIDA Pharmaceuticals, Inc. 140
MethylGene Inc 140
NexMed, Inc. 141
Accentia Biopharmaceuticals, Inc. 141
Keryx Biopharmaceuticals, Inc. 142
Allos Therapeutics, Inc 142
BioCryst Pharmaceuticals, Inc. 143
Portola Pharmaceuticals, Inc. 144
Cytokinetics, Inc 144
Telik, Inc. 144
TopoTarget A/S 145
Mundipharma International Limited 145
Pharmacyclics, Inc. 146
MorphoSys AG 146
LG Life Sciences, Ltd 147
Sareum Holdings plc 147
Innate Pharma SA 148
Piramal Life Sciences Limited 148
SymBio Pharmaceuticals Limited 149
Ospedali Riuniti di Bergamo 149
Affimed Therapeutics AG 150
Chipscreen Biosciences Ltd 150
Memgen, LLC. 151
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
PanGenetics B.V. 151
Abiogen Pharma S.p.A. 151
TRION Pharma GmbH 152
MAT Biopharma 152
Biolex Therapeutics, Inc. 153
Ascenta Therapeutics, Inc. 153
Provenance Biopharmaceuticals Corp. 153
Pharmascience Inc. 154
Semafore Pharmaceuticals, Inc. 154
S*BIO Pte Ltd 155
ProNAi Therapeutics, Inc. 155
Avila Therapeutics, Inc. 155
Yaupon Therapeutics, Inc. 156
Onconova Therapeutics, Inc 156
NOXXON Pharma AG 157
Xencor, Inc. 157
PharmaMar, S.A. 157
Bellicum Pharmaceuticals, Inc. 158
VentiRx Pharmaceuticals, Inc. 158
Prospect Therapeutics, Inc. 159
CureTech Ltd. 159
Hy BioPharma Inc. 159
Nereus Pharmaceuticals, Inc. 160
Archer Biosciences, Inc 160
Averion, Inc. 161
Dynamix Pharmaceuticals Ltd. 161
Zenyaku Kogyo Co., Ltd. 161
EpiZyme, Inc. 162
Probiomed S.A. de C.V. 162
Theradex Systems, Inc. 162
PharmaTech International, Inc. 163
Pharmatech Oncology, Inc 163
Non-Hodgkin Lymphoma - Therapeutics Assessment 164
Assessment by Monotherapy Products 164
Assessment by Combination Products 165
Assessment by Route of Administration 166
Assessment by Molecule Type 169
Late Stage Drug Profiles 172
StemEx - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 172
RG7159 - Drug Profile 173
Product Description 173
Mechanism of Action 173
R&D Progress 173
MAbThera - Drug Profile 174
Product Description 174
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Mechanism of Action 174
R&D Progress 174
MAbThera - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
Adcetris - Drug Profile 178
Product Description 178
Mechanism of Action 178
R&D Progress 178
Arzerra - Drug Profile 180
Product Description 180
Mechanism of Action 180
R&D Progress 180
BiovaxID - Drug Profile 183
Product Description 183
Mechanism of Action 183
R&D Progress 183
Pixantrone - Drug Profile 184
Product Description 184
Mechanism of Action 184
R&D Progress 184
Velcade - Drug Profile 186
Product Description 186
Mechanism of Action 186
R&D Progress 186
SyB L-0501 - Drug Profile 187
Product Description 187
Mechanism of Action 187
R&D Progress 187
Forodesine - Drug Profile 188
Product Description 188
Mechanism of Action 188
R&D Progress 188
Clearazide - Drug Profile 190
Product Description 190
Mechanism of Action 190
R&D Progress 190
ONTAK - Drug Profile 191
Product Description 191
Mechanism of Action 191
R&D Progress 191
Folotyn - Drug Profile 193
Product Description 193
Mechanism of Action 193
R&D Progress 193
HuMax-CD4 - Drug Profile 195
Product Description 195
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Mechanism of Action 195
R&D Progress 195
Epratuzumab - Drug Profile 197
Product Description 197
Mechanism of Action 197
R&D Progress 197
Rituximab - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 199
Product Description 199
Mechanism of Action 199
R&D Progress 199
CHOP-14 + Alemtuzumab - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 201
Bendamustine + Rituximab - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile 203
Product Description 203
Mechanism of Action 203
R&D Progress 203
Rituximab + Chlorambucil - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 204
Rituximab - Drug Profile 205
Product Description 205
Mechanism of Action 205
R&D Progress 205
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 206
Product Description 206
Mechanism of Action 206
R&D Progress 206
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 208
Product Description 208
Mechanism of Action 208
R&D Progress 208
Chlorambucil For Follicular lymphoma - Drug Profile 210
Product Description 210
Mechanism of Action 210
R&D Progress 210
Velcade + Rituximab - Drug Profile 211
Product Description 211
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(6)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Mechanism of Action 211
R&D Progress 211
CMC-544 - Drug Profile 212
Product Description 212
Mechanism of Action 212
R&D Progress 212
CMC-544 + Rituxan - Drug Profile 213
Product Description 213
Mechanism of Action 213
R&D Progress 213
SDX-105 + Rituxan - Drug Profile 214
Product Description 214
Mechanism of Action 214
R&D Progress 214
Revlimid - Drug Profile 215
Product Description 215
Mechanism of Action 215
R&D Progress 215
R05072759 + Bendamustine - Drug Profile 217
Product Description 217
Mechanism of Action 217
R&D Progress 217
Arzerra + Bendamustine - Drug Profile 218
Product Description 218
Mechanism of Action 218
R&D Progress 218
Pixantrone + Rituximab + Fludarabine - Drug Profile 220
Product Description 220
Mechanism of Action 220
R&D Progress 220
Pixantrone + Rituximab - Drug Profile 222
Product Description 222
Mechanism of Action 222
R&D Progress 222
Avastin + R-CHOP - Drug Profile 223
Product Description 223
Mechanism of Action 223
R&D Progress 224
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 225
Product Description 225
Mechanism of Action 225
R&D Progress 226
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 228
Product Description 228
Mechanism of Action 228
R&D Progress 229
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 230
Product Description 230
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(7)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Mechanism of Action 230
R&D Progress 230
CHOP14 + G-CSF + MabCampath - Drug Profile 231
Product Description 231
Mechanism of Action 231
R&D Progress 232
Rituximab + CHOP - Drug Profile 233
Product Description 233
Mechanism of Action 233
R&D Progress 233
EPOCH + Rituximab - Drug Profile 235
Product Description 235
Mechanism of Action 235
R&D Progress 236
Rituximab - Drug Profile 237
Product Description 237
Mechanism of Action 237
R&D Progress 237
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine +
Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 239
RO5072759 + Bendamustine - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
ONTAK - Drug Profile 242
Product Description 242
Mechanism of Action 242
R&D Progress 242
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 243
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile 245
Product Description 245
Mechanism of Action 245
R&D Progress 246
Rituximab - Drug Profile 247
Product Description 247
Mechanism of Action 247
R&D Progress 247
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 248
Product Description 248
Mechanism of Action 248
R&D Progress 248
R-CHOP - Drug Profile 249
Product Description 249
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(8)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Mechanism of Action 249
R&D Progress 249
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Cisplatin + Dexamethasone + Cytarabine + Melphalan + Radiation
Therapy + Stem Cell Transplantation - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 252
CHEOP + Radiation Therapy - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 254
R-CHOP + Radiation Therapy - Drug Profile 255
Product Description 255
Mechanism of Action 255
R&D Progress 256
Rituximab - Drug Profile 257
Product Description 257
Mechanism of Action 257
R&D Progress 257
PMitCEBO - Drug Profile 259
Product Description 259
Mechanism of Action 259
R&D Progress 260
CHOP Regimen - Drug Profile 261
Product Description 261
Mechanism of Action 261
R&D Progress 261
Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile 263
Product Description 263
Mechanism of Action 263
R&D Progress 263
Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
265
Product Description 265
Mechanism of Action 265
R&D Progress 265
Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile 266
Product Description 266
Mechanism of Action 266
R&D Progress 266
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 267
Product Description 267
Mechanism of Action 267
R&D Progress 268
Chlorambucil + Dexamethasone + Idarubicin + Recombinant Interferon Alfa - Drug Profile 269
Product Description 269
Mechanism of Action 269
R&D Progress 269
Chlorambucil + Dexamethasone + Recombinant Interferon Alfa - Drug Profile 271
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(9)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Product Description 271
Mechanism of Action 271
R&D Progress 271
Rituximab - Drug Profile 273
Product Description 273
Mechanism of Action 273
R&D Progress 273
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine +
Methotrexate + Prednisolone + Thioguanine + Vincristine Sulfate - Drug Profile 274
Product Description 274
Mechanism of Action 274
R&D Progress 275
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 277
Product Description 277
Mechanism of Action 277
R&D Progress 278
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile 279
Product Description 279
Mechanism of Action 279
R&D Progress 280
Fludarabine - Drug Profile 281
Product Description 281
Mechanism of Action 281
R&D Progress 281
FavId + Sargramostim + Rituximab - Drug Profile 282
Product Description 282
Mechanism of Action 282
R&D Progress 282
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile 284
Product Description 284
Mechanism of Action 284
R&D Progress 285
Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile 286
Product Description 286
Mechanism of Action 286
R&D Progress 287
Bexarotene + PUVA - Drug Profile 288
Product Description 288
Mechanism of Action 288
R&D Progress 288
Rituximab + CHOP - Drug Profile 289
Product Description 289
Mechanism of Action 290
R&D Progress 290
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 291
Product Description 291
Mechanism of Action 291
R&D Progress 291
R-CHOP14 + Neulasta - Drug Profile 293
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(10)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Product Description 293
Mechanism of Action 293
R&D Progress 293
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile 295
Product Description 295
Mechanism of Action 295
R&D Progress 295
Rituxan + FavId + GM-CSF - Drug Profile 297
Product Description 297
Mechanism of Action 297
R&D Progress 297
DHAP + Rituximab - Drug Profile 298
Product Description 298
Mechanism of Action 298
R&D Progress 298
ICE + RITUXIMAB - Drug Profile 299
Product Description 299
Mechanism of Action 299
R&D Progress 299
CHOP Regimen + Filgrastim + Cytarabine + Etoposide + Leucovorin Calcium + Melphalan + Methotrexate + Methylprednisolone +
Mitoxantrone Hydrochloride + Hydrocortisone + Autologous Stem Cell Transplantation + Radiation Therapy - Drug Profile 300
Product Description 300
Mechanism of Action 300
R&D Progress 301
Filgrastim + Rituximab + Sargramostim + CHOP regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide +
Prednisone + Vincristine sulfate - Drug Profile 302
Product Description 302
Mechanism of Action 303
R&D Progress 304
Filgrastim + Rituximab + Sargramostim + CHOP regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide +
Prednisone + Vincristine sulfate - Drug Profile 305
Product Description 305
Mechanism of Action 305
R&D Progress 307
Ifosfamide + Amsacrine + Etoposide - Drug Profile 308
Product Description 308
Mechanism of Action 308
R&D Progress 308
Rituxan + CHOP Chemotherapy - Drug Profile 309
Product Description 309
Mechanism of Action 309
R&D Progress 309
rituximab + cisplatin + cytarabine + dexamethasone + gemcitabine hydrochloride - Drug Profile 311
Product Description 311
Mechanism of Action 311
R&D Progress 311
Dexamethasone + Cisplatin + Cytarabine + Etoposide + Ifosfamide + Methotrexate + G-CSF - Drug Profile 313
Product Description 313
Mechanism of Action 313
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(11)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
R&D Progress 314
Dexamethasone + Cisplatin + Cytarabine + Etoposide + Ifosfamide + Methotrexate + G-CSF + Rituximab - Drug Profile 315
Product Description 315
Mechanism of Action 316
R&D Progress 316
Hypericin - Drug Profile 318
Product Description 318
Mechanism of Action 318
R&D Progress 318
Mega-CHOEP + Rituximab + Autologous Stem Cell Transplantation - Drug Profile 319
Product Description 319
Mechanism of Action 319
R&D Progress 320
Etoposide + Ifosfamide + Cisplatin + Doxorubicin + Bleomycin + Vinblastine + Dacarbazine + Radiation Therapy - Drug Profile 321
Product Description 321
Mechanism of Action 322
R&D Progress 323
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 324
Product Description 324
Mechanism of Action 324
R&D Progress 325
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile 326
Product Description 326
Mechanism of Action 326
R&D Progress 327
Chlorambucil + Dexamethasone + Interferon alfa - Drug Profile 329
Product Description 329
Mechanism of Action 329
R&D Progress 329
Chlorambucil + Idarubicin + Dexamethasone + Interferon alfa - Drug Profile 331
Product Description 331
Mechanism of Action 331
R&D Progress 332
Carmustine + Cyclophosphamide + Cytarabine + Doxorubicin + Etoposide + Melphalan + Prednisone + Vincristine + Stem Cell Transplantation
- Drug Profile 333
Product Description 333
Mechanism of Action 334
R&D Progress 335
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 336
Product Description 336
Mechanism of Action 336
R&D Progress 337
R-FM - Drug Profile 338
Product Description 338
Mechanism of Action 338
R&D Progress 338
R-CVP - Drug Profile 340
Product Description 340
Mechanism of Action 340
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(12)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
R&D Progress 341
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile 342
Product Description 342
Mechanism of Action 342
R&D Progress 343
cyclophosphamide + prednisone + vincristine sulfate + rituximab - Drug Profile 344
Product Description 344
Mechanism of Action 344
R&D Progress 345
Filgrastim + Rituximab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile 346
Product Description 346
Mechanism of Action 347
R&D Progress 347
R-CHOP14 + Darbepoetin Alfa - Drug Profile 349
Product Description 349
Mechanism of Action 349
R&D Progress 350
Rituximab-HDS - Drug Profile 351
Product Description 351
Mechanism of Action 351
R&D Progress 351
Asparaginase + Cyclophosphamide + Cytarabine + Aunorubicin Hydrochloride + Dexamethasone + Doxorubicin Hydrochloride + Etoposide +
Leucovorin Calcium + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisolone + Therapeutic
Hydrocortisone + Thioguanine + Vincristine Sulfate + Vindesine - Drug Profile 352
Product Description 352
Mechanism of Action 353
R&D Progress 355
cyclophosphamide + mitoxantrone hydrochloride + prednisolone + vincristine sulfate - Drug Profile 357
Product Description 357
Mechanism of Action 357
R&D Progress 358
Filgrastim + Recombinant Interferon Alfa + Cyclophosphamide + Prednisone + Vincristine Sulfate - Drug Profile 359
Product Description 359
Mechanism of Action 359
R&D Progress 360
Rituximab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile 361
Product Description 361
Mechanism of Action 361
R&D Progress 362
Aldesleukin + Filgrastim + Cyclophosphamide + Etoposide + Peripheral Stem Cell Transplantation + Radiation Therapy - Drug Profile 363
Product Description 363
Mechanism of Action 363
R&D Progress 363
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisolone + Autologous Bone Marrow Transplantation
+ Radiation Therapy - Drug Profile 365
Product Description 365
Mechanism of Action 365
R&D Progress 366
bleomycin sulfate + rituximab + CHOP regimen + EPOCH regimen + cyclophosphamide + doxorubicin hydrochloride + etoposide +
methotrexate + mitoxantrone hydrochloride + prednisolone + prednisone + vincristine sulfate - Drug Profile 368
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011 GMDHC1309IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(13)
Non-Hodgkin Lymphoma – Pipeline Review, H2 2011
Product Description 368
Mechanism of Action 369
R&D Progress 370
filgrastim + recombinant interferon alfa + carmustine + cyclophosphamide + cytarabine + dexamethasone + etoposide + melphalan - Drug
Profile 372
Product Description 372
Mechanism of Action 373
R&D Progress 373
Rituximab + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine sulfate + filgrastim + carboplatin + etoposide +
ifosfamide - Drug Profile 375
Product Description 375
Mechanism of Action 376
R&D Progress 377
Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Filgrastim - Drug Profile 378
Product Description